HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., March 22, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated the registration stage of the Phase II/III clinical trial of sovleplenib in adult patients with warm antibody autoimmune hemolytic anemia ("wAIHA") in China. This follows positive data from the proof-of-concept Phase II stage of the trial and subsequent consultation with the China National Medical Products Administratio ...

HUTCHMED (China) Limited (NASDAQ:HCM) Q4 2023 Results Conference Call February 28, 2024 7:30 AM ET Company Participants Mark Lee - Senior Vice President of Corporate Management & Communications Dr. Wei-Guo Su - CEO, Chief Scientific Officer Johnny Cheng - CFO Zhenping Wu - Executive Vice President of Pharmaceutical Science & Manufacturing Michael Shi - Executive VP, Head of R&D and Chief Medical Officer Conference Call Participants Louise Alesandra Chen - Cantor Fitzgerald & Co Alec Warren Stranahan - Bank ...

Revenue grew 97% (102% CER) to US$838 million, with net income of US$101 million First U.S. FDA approval of our self-developed medicine, FRUZAQLA™ (fruquintinib) Sovleplenib for ITP accepted for NDA review in China, with Priority Review status and Breakthrough Therapy designation HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Feb. 28, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED", the "Company" or "we") (Nasdaq/AIM:​HCM; HKEX:​13), the innovative, commercial-stage biopharmaceutical co ...

Exhibit 99.1 HUTCHMED Reports 2023 Full Year Results and Provides Business Updates Revenue grew 97% (102% CER) to US$838 million, with net income of US$101 million First U.S. FDA approval of our self-developed medicine, FRUZAQLA™ (fruquintinib) Sovleplenib for ITP accepted for NDA review in China, with Priority Review status and Breakthrough Therapy designation Hong Kong, Shanghai & Florham Park, NJ — Wednesday, February 28, 2024: HUTCHMED (China) Limited (“HUTCHMED”, the “Company” or “we”) (Nasdaq/AIM:HCM; ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark one) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF ...

Shares of HUTCHMED (HCM) have gained 2.2% over the past four weeks to close the last trading session at $14.59, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $25.54 indicates a potential upside of 75.1%.The average comprises five short-term price targets ranging from a low of $14.60 to a high of $45, with a standard deviation of $12.20. While the lowest estimate indicates an i ...

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Feb. 06, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:​HCM; HKEX:​13) today announces that data from FRUTIGA, HUTCHMED's Phase III trial of fruquintinib in combination with paclitaxel for the treatment of second-line advanced gastric cancer in China, were presented at the American Society of Clinical Oncology ("ASCO") Plenary Series Session on February 6, 2024. The full presentation can be found here. Fruquintinib is a selec ...

Inmagene exercised its option under the previously announced collaboration agreement to obtain an exclusive, royalty-bearing license for IMG-007, an anti-OX40 monoclonal antibody (mAb) and IMG-004, a Bruton Tyrosine Kinase (BTK) inhibitor Inmagene retains rights to develop and commercialize both assets worldwide SAN DIEGO, Feb. 2, 2024 /PRNewswire/ -- Inmagene Biopharmaceuticals ("Inmagene" or the "Company"), a clinical stage biotechnology company developing innovative and differentiated therapies for imm ...

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Feb. 02, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:​HCM; HKEX:​13) today announced that, Inmagene Biopharmaceuticals ("Inmagene") has exercised options to license two drug candidates discovered by HUTCHMED, IMG-007 and IMG-004 (the "Options") pursuant to the terms of the strategic partnership announced on January 11, 2021. Following the exercise of the Options and subject to receipt by HUTCHMED of ordinary shares represen ...

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Feb. 01, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM: HCM; SEHK:13) will be announcing its final results for the year ended December 31, 2023 on Wednesday, February 28, 2024 at 6:30 am Eastern Standard Time (EST) / 11:30 am Greenwich Mean Time (GMT) / 7:30 pm Hong Kong Time (HKT). Analysts and investors are invited to join a conference call and audio webcast presentation with Q&A, conducted by HUTCHMED management. The Engli ...